News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


ONC201 Investigator Meeting and Clinical Efficacy in H3 K27M-mutant Glioma to be Presented at Society for Neuro-Oncology Conference


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 I am a little biased on this one as we gave them 3 grants - including our largest ever - to help get them to this point.  They will be  presenting 10 abstracts at next week's Society for Neuro-Oncology conference in New Orleans.  This experimental drug - Onc-201 is the first of it's class - a DRD2/ DRD3 antagonist. Early results were very impressive, and we are hoping they present exciting news next week!   


Posted on: 11/07/2018

ONC201 Investigator Meeting and Clinical Efficacy in H3 K27M-mutant Glioma to be Presented at Society for Neuro-Oncology Conference 

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740